UNCY, US90466Y2028

Unicycive faces November 2 lawsuit deadline: Unicycive Therapeutics stock sits at USD 98.3 million

Published on 10/16/2026 at 04:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The complaint sets a November 2 lead plaintiff date. For Unicycive Therapeutics stock, cash and securities totaled USD 61.4 million.

Regulatory and legal milestones

A shareholder lawsuit sets November 2, 2026, as the lead plaintiff deadline.
Unicycive's September 29, 2026, filing included 12 months of stability data.
Unicycive Therapeutics stock had a USD 98.3 million market capitalization on October 15, 2026.
Meredith Manning brought more than 25 years of biopharmaceutical experience to the board on October 1, 2026.

UNCY, US90466Y2028, Illustration mit AI erstellt.

Unicycive Therapeutics (ISIN US90466Y2028) faces a November 2, 2026, deadline for investors seeking lead plaintiff status in a shareholder lawsuit, as GlobeNewswire reported on October 14, 2026. The legal case centers on disclosures surrounding the manufacturing arrangements for oxylanthanum carbonate, the company's lead drug candidate.

Three milestones since June

On June 30, 2026, Unicycive disclosed a second Complete Response Letter from the U.S. Food and Drug Administration concerning the drug application. The stock closed at USD 4.69 that day after a USD 3.01 decline, or 39.10 percent, according to the lawsuit notice carried by GlobeNewswire.

On September 29, 2026, the company resubmitted its New Drug Application for oxylanthanum carbonate with data from a new manufacturing vendor. The package included 12 months of drug product stability data, and the company said it expected FDA acceptance within 30 days, according to GlobeNewswire.

What does the filing mean?

The legal proceeding adds a disclosure risk to a regulatory story that still depends on manufacturing execution. Unicycive said cash, cash equivalents and marketable securities totaled USD 61.4 million as of June 30, 2026, supporting an expected runway into the second half of 2027. That liquidity gives the company time to prepare for a potential launch, but FDA acceptance and later approval remain separate milestones.

On October 1, 2026, Unicycive appointed Meredith Manning to its board. The company said she brought more than 25 years of global biopharmaceutical experience, including commercial launches and regulatory work.

Next date for shareholders

The next concrete date is November 2, 2026, when motions to seek lead plaintiff status are due. The September 29 filing also pointed to a new PDUFA date expected six months after resubmission, subject to FDA acceptance.

Market value stays below USD 100 million

Unicycive Therapeutics had a market capitalization of USD 98.3 million on October 15, 2026. Its 52-week range was USD 3.56 to USD 8.74, keeping the regulatory timeline and financing runway central to the investment case.